Highlights Ocugen, Inc.

Equities

OCGN

US67577C1053

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-08 EDT			Pre-market 08:16:08
1.72 ^USD	+9.55%		1.74	+1.16%

04-29	Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024	CI
04-22	Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024	04-29	CI
Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration	04-19	MT
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy	04-19	CI
Ocugen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for Ocu400?Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication	04-10	CI
Ocugen Gets FDA Clearance for IND Amendment for OCU400	04-08	DJ
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial	04-08	CI
Sector Update: Health Care Stocks Rise Late Afternoon	04-05	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	04-05	MT
Ocugen Says Data, Safety Monitoring Board Issues 'Positive' Review of Eye Disease Treatment -- Shares Rise	04-05	MT
Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy	04-05	CI
Sector Update: Health Care Stocks Slipping in Afternoon Trading	04-02	MT
Ocugen to Restate Financial Statements; Shares Tumble	04-02	MT
Ocugen Provides Business Update	04-02	CI
North American Morning Briefing : Stocks Seen -2-	04-02	DJ
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410st?A Modifier Gene Therapy?In Gardian Study for Stargardt Disease	04-01	CI
Sector Update: Health Care Stocks Steady Premarket Monday	03-25	MT
Sector Update: Health Care Stocks Ease Late Afternoon	03-22	MT
Ocugen Stock Rallies After Appeals Court Dismisses Allegations of Misleading Shareholders	03-22	MT
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410	03-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ocugen, Inc.

Equities

OCGN

US67577C1053

Highlights

Filters